Financial Review: Tyra Biosciences (NASDAQ:TYRA) versus Oncocyte (NASDAQ:IMDX)

Oncocyte (NASDAQ:IMDX) and Tyra Biosciences (NASDAQ:TYRA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, analyst recommendations, dividends and profitability.

Volatility & Risk

Oncocyte has a beta of 1.8, suggesting that its share price is 80% more volatile than the S&P 500. Comparatively, Tyra Biosciences has a beta of 0.73, suggesting that its share price is 27% less volatile than the S&P 500.

Earnings & Valuation

This table compares Oncocyte and Tyra Biosciences”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncocyte	$4.05 million	33.37	-$50.22 million	($1.49)	-2.77
Tyra Biosciences	N/A	N/A	-$119.95 million	($2.40)	-11.94

Oncocyte has higher revenue and earnings than Tyra Biosciences. Tyra Biosciences is trading at a lower price-to-earnings ratio than Oncocyte, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

55.3% of Oncocyte shares are owned by institutional investors. Comparatively, 84.1% of Tyra Biosciences shares are owned by institutional investors. 2.2% of Oncocyte shares are owned by insiders. Comparatively, 12.5% of Tyra Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Oncocyte and Tyra Biosciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncocyte	1	0	2	0	2.33
Tyra Biosciences	1	1	12	0	2.79

Oncocyte currently has a consensus target price of $10.50, indicating a potential upside of 154.24%. Tyra Biosciences has a consensus target price of $48.22, indicating a potential upside of 68.31%. Given Oncocyte’s higher possible upside, equities analysts clearly believe Oncocyte is more favorable than Tyra Biosciences.

Profitability

This table compares Oncocyte and Tyra Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oncocyte	-2,955.63%	N/A	-107.52%
Tyra Biosciences	N/A	-46.39%	-43.07%

Summary

Oncocyte beats Tyra Biosciences on 7 of the 13 factors compared between the two stocks.

About Oncocyte

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

About Tyra Biosciences

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.